Filing Flows › Moderna (MRNA) › Guidance & outlook

Moderna (MRNA) guidance and outlook

Moderna (MRNA) raised some and lowered other parts of its guidance on Nov 6, 2026: Revenue +15% to +25% for FY2026; Revenue $1.7B for FY2026.

Guidance and outlook

Met or beat 1 of 1 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.

Latest guidance

Metric	Period	Range	Change
Revenue	FY2026	+15% to +25%	raised
Revenue	FY2026	$1.7B	reaffirmed
Capital expenditures	FY2026	$200M	lowered

From the earnings release filed Nov 6, 2026 (8-K on EDGAR).

Moderna's latest quarter

Moderna, Q3 2026: revenue $1.3B (+29% year over year), operating margin 9.9%, net earnings $162M, operating cash flow −$1.6B. The chart follows the revenue to costs, profit and cash.

Questions

Did Moderna raise or lower its guidance?

Moderna (MRNA) raised some and lowered other parts of its guidance on Nov 6, 2026: Revenue +15% to +25% for FY2026; Revenue $1.7B for FY2026.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.